Skip to main
ACIU

AC Immune (ACIU) Stock Forecast & Price Target

AC Immune (ACIU) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

AC Immune is a promising biopharmaceutical company with a robust portfolio of programs focused on developing effective treatments for neurodegenerative diseases. Its use of proprietary technology platforms provides an advantage in discovering and developing innovative therapies for Alzheimer's and Parkinson's diseases. With a strong pipeline consisting of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others, as well as promising financials and partnerships with top pharmaceutical companies like Takeda, AC Immune is well positioned for success in the neurodegenerative disease market.

Bears say

AC Immune is a clinical stage biopharmaceutical company with a focus on Precision Medicine for neurodegenerative diseases, using technology platforms to develop therapeutic and diagnostic products targeting misfolded proteins. Their current pipeline includes several potential treatments, with key programs ACI-24.060 and ACI-35.030 targeting MCI and preclinical AD, respectively. However, despite the potential for market entry in 2030-2031 with estimated pricing of $26,500 per patient per year, the limited success and challenges faced in their AD4 Cohort suggest a high level of risk for investors.

AC Immune (ACIU) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AC Immune and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AC Immune (ACIU) Forecast

Analysts have given AC Immune (ACIU) a Strong Buy based on their latest research and market trends.

According to 1 analysts, AC Immune (ACIU) has a Strong Buy consensus rating as of Jun 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AC Immune (ACIU)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.